ABSTRACT
EPIDEMIOLOGY OF SUBSTANCE-INDUCED INSOMNIA Substance-induced insomnia (SII) is characterized by disruption of sleep and adverse daytime consequences during periods of use or withdrawal from illicit drugs, prescription medications, or licit substances (i.e. alcohol, caffeine, toxins or food items). SII does not result exclusively from substance abuse, but can also develop over time through repeated exposure to a prescribed dosage of a medication. SII is found in approximately 0.2% of the general population, but can comprise up to 3.5% of the sleep disorders clinic population (1). Not unexpectedly, rates are considerably higher in patients presenting for substance abuse treatment. Up to 91% of alcoholdependent patients, for example, have symptoms of insomnia (2).
